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Abstract
Background: The insulin-like growth factor 1 (IGF-1) pathway is involved in cell growth and proliferation and is
associated with tumorigenesis and therapy resistance. This study aims to elucidate whether variation in the IGF-1
pathway is predictive for pathologic response in early HER2 negative breast cancer (BC) patients, taking part in the
phase III NEOZOTAC trial, randomizing between 6 cycles of neoadjuvant TAC chemotherapy with or without
zoledronic acid.
Methods: Formalin-fixed paraffin-embedded tissue samples of pre-chemotherapy biopsies and operation specimens
were collected for analysis of IGF-1 receptor (IGF-1R) expression (n = 216) and for analysis of 8 candidate single
nucleotide polymorphisms (SNPs) in genes of the IGF-1 pathway (n = 184) using OpenArray® RealTime PCR.
Associations with patient and tumor characteristics and chemotherapy response according to Miller and Payne
pathologic response were performed using chi-square and regression analysis.
Results: During chemotherapy, a significant number of tumors (47.2 %) showed a decrease in IGF-1R expression, while
in a small number of tumors an upregulation was seen (15.1 %). IGF-1R expression before treatment was not associated
with pathological response, however, absence of IGF-1R expression after treatment was associated with a better
response in multivariate analysis (P = 0.006) and patients with a decrease in expression during treatment showed a
better response to chemotherapy as well (P = 0.020). Moreover, the variant T allele of 3129G > T in IGF1R (rs2016347)
was associated with a better pathological response in multivariate analysis (P = 0.032).
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Conclusions: Absent or diminished expression of IGF-1R after neoadjuvant chemotherapy was associated with
a better pathological response. Additionally, we found a SNP (rs2016347) in IGF1R as a potential predictive
marker for chemotherapy efficacy in BC patients treated with TAC.
Trial registration: ClinicalTrials.gov NCT01099436. Registered April 6, 2010.
Keywords: Breast cancer, Neoadjuvant chemotherapy, Glucose, Insulin, IGF-1, IGF-BP3, IGF-1R, Miller and Payne,
Pathological complete response, Single nucleotide polymorphisms
Background
Insulin-like growth factor (IGF)-1 and other members of
the IGF-1 pathway have been associated with develop-
ment, progression, and metastasis of several cancers [1, 2].
Additionally, epidemiologic studies have shown a relation
between high circulating IGF-1 levels, breast density [3],
and risk of breast cancer (BC) [4]. Increased IGF-1 levels
are associated with an elevated BC mortality [5] and with
inherent resistance to anti-tumor treatments in preclinical
models [6–9]. Furthermore, the IGF-1 receptor (IGF-1R),
a transmembrane tyrosine kinase, is frequently upregu-
lated in BC [10, 11]. The biological activity of IGF-1
and IGF-2 depends on binding with the insulin-like
growth factor binding proteins (IGF-BPs), mainly IGF-
BP3 [12, 13]. Both IGFs bind the IGF-1R and activate
the Ras/mitogen-activated protein kinase (MAPK)
and phosphatidylinositol-3-kinase (PI3K)/AKT pathways,
through which cell proliferation is stimulated and
apoptosis is inhibited, respectively [14, 15]. Addition-
ally, the IGF-1R and the estrogen receptor (ER) have been
shown to work synergistically, whereby activated ER binds
to the promoter regions of IGF1R to promote transcrip-
tion and IGF-1 is able to activate unliganded ER [16, 17].
Previous research has shown that low IGF-1R expres-
sion in the tumor is predictive for pathological complete
response (pCR) in ER-positive tumors [10] and that up-
regulation of IGF-1R during chemotherapy predicts a
poor outcome in a relative small, heterogeneous group
of BC patients [18]. Moreover, genes encoding members
of the IGF-1 pathway are known to harbor several single
nucleotide polymorphisms (SNPs) that influence the ac-
tivity of the pathway. SNPs associated with IGF-1 and
IGF-BP3 plasma levels and breast density are described
[19, 20] as well as SNPs associated with therapy resist-
ance and outcome [21, 22].
Neoadjuvant chemotherapy has been demonstrated to be
equivalent to adjuvant chemotherapy for BC survival. This
treatment has the advantage of more frequent breast-
conserving therapy [23] and offers the opportunity for
translational research of molecular predictors of tumor
response. Additionally, the Miller and Payne (MP) histo-
logical grading system can be used to assess response to
neoadjuvant chemotherapy because it is associated with
patients’ disease-free and overall survival [24, 25]. This
study evaluates the expression of the IGF-1R of the tumor
before and after neoadjuvant chemotherapy and whether it
predicts pathological response according to MP classifica-
tion after neoadjuvant chemotherapy in human epidermal
growth factor receptor 2 (HER2)-negative early BC patients
treated in the NEOZOTAC trial [26]. Moreover, we aim to
identify SNPs, which have been described to influence the
activity of the IGF-1 pathway, to predict chemotherapy effi-
cacy in this cohort. In addition, these SNPs are tested for
association with the occurrence of side effects.
Methods
Study population
From July 2010 until April 2012, 250 women partici-
pated in the multicenter phase III NEOZOTAC trial,
randomizing between TAC chemotherapy (75 mg/m2
docetaxel, 50 mg/m2 doxorubicin, and 500 mg/m2 cyclo-
phosphamide) with or without zoledronic acid (4 mg
within 24 hours after chemotherapy). Eligible patients
had a histologically confirmed diagnosis of HER2-
negative stage II or III BC. Other inclusion and exclu-
sion criteria have been described elsewhere [26]. Tumor
regression was scored according to the MP classification
[24]. pCR was defined as the absence of residual invasive
cancer within the breast and lymph nodes [24]. Side
effects and hematological toxicity were graded according
to the Common Terminology Criteria for Adverse
Events version 4.0 (CTCAE v.4.0) [27]. All patients gave
written informed consent. The study was conducted in
accordance with the Declaration of Helsinki (2008)
and approved by the Ethics Committee of the Leiden
University Medical Center in agreement with the Dutch
law for medical research involving humans.
Immunohistochemistry
Formalin-fixed paraffin-embedded (FFPE) tumor tissue
samples of prechemotherapy biopsies and operation
specimens were collected for analysis of IGF-1R expres-
sion using immunohistochemistry (IHC). From each
FFPE tumor tissue sample, one section of 4 μm was cut
and deparaffinized with xylene, rehydrated through
graded alcohol, and rinsed in distilled water. After block-
ing of endogenous peroxidase activity with 0.3 % H2O2
for 20 minutes, heat-induced antigen retrieval was
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performed in the EnVision™ Flex Target Retrieval Solution
in PT Link (Dako, Glostrup, Denmark) at low pH. After
blocking with 5 % normal goat serum to reduce aspecific
binding by the primary antibody, the sections were incu-
bated overnight at room temperature in a humidified
chamber with the IGF-1R antibody (IGF-1 receptor β,
D4O6W, rabbit monoclonal; Cell Signaling Technology,
Danvers, MA, USA) diluted in phosphate-buffered saline
(PBS)/bovine serum albumin (BSA) 1 % at a dilution of
1:200. After the primary antibody incubation, the sections
were washed with PBS and incubated with a secondary
anti-rabbit antibody EnVision™ (Dako, Glostrup, Denmark)
for 30 minutes and visualized using liquid DAB+ (Dako,
Glostrup, Denmark). Eventually, sections were coun-
terstained with Mayer’s hematoxylin, dehydrated, and
subsequently permanently mounted with Pertex (Histo-
lab, Gothenburg, Sweden). Breast and placenta sections that
had previously been identified to express the IGF-1R were
used as positive controls, and sections that underwent the
IHC staining procedure without application of primary
antibodies served as negative controls. Membranous IGF-
1R expression was scored on a scale of 0–3+ (see Fig. 1).
Samples were considered negative if 0 or 1+ was scored,
and positive if 2+ and 3+ was given. The staining was
scored by two independent researchers (SdG and ALM).
SNP selection
To select relevant SNPs in the IGF-1 pathway, a
PubMed search with the keywords “IGF-1”, “IGF-2”,
“IGF-BP3”, “IGF-1R”, “single nucleotide polymorphism”,
“breast cancer”, and/or “clinical outcome” was conducted
in July 2013. SNPs that were associated with IGF-1 or
IGF-BP3 plasma levels, BC risk, or clinical outcome in
cancer patients treated with chemotherapy, were selected.
SNPs with a minor allele frequency (MAF) >0.01 in a
Caucasian population according to the HapMap project
database and with a potential functionality according to
the literature review or using national institutes of health
functionality database were selected [28]. To minimize the
number of tested associations, tagging SNPs were selected
for SNPs that were in linkage disequilibrium (r2 > 0.7).
The selected SNPs in the IGF1, IGF2, IGFBP3, and IGF1R
genes are summarized in Table 1.
DNA isolation and preamplification
DNA was extracted from FFPE tissue samples. Preferen-
tially, tissue from tumor-negative breast tissue and
tumor-negative lymph nodes was used (N = 95); however,
when this was unavailable or unclear from the pathology
report tissue from tumor-containing blocks was used.
Three sections of 4 μm were incubated overnight at 50 °C
in 500 μl lysis buffer (NH4Cl 8.4 g/l, KHCO3 1.0 g/l, pro-
teinase K 0.25 mg/ml). Next, 300 μl was taken to extract
DNA using the Maxwell forensic DNA isolation kit
(Promega, Leiden, the Netherlands) according to the
manufacturer’s protocol. DNA isolated from FFPE tis-
sue is cross-linked and fragmented into pieces with a
length of a few hundred base pairs. To make DNA
isolated from FFPE tissue more suitable for genotyp-
ing, preamplification was accomplished for enrich-
ment of the target DNA [29]. The preamplification
Fig. 1 Examples of the membranous IGF-1R staining in breast tumor tissue sections. Score 0: staining is observed in <10 % of the tumor cells.
Score 1+: incomplete staining is observed in >10 % of the tumor cells, Score 2+: weak or moderate complete staining is observed in >10 % of the
tumor cells, Score 3+: strong complete staining is observed >10 % of tumor cells. Samples were considered negative if 0 or 1+ was scored, and
positive if 2+ and 3+ was given
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step consisted of a PCR reaction with eight diluted
TaqMan assays (LifeTechnologies, Nieuwerkerk aan den
IJssel, the Netherlands) and was performed using the fol-
lowing protocol; to 2.5 μl DNA, 1 μl of a dilution of eight
TaqMan assays (pooled at a final concentration of 0.2×)
and 3.5 μl HotStarTaq DNA polymerase was added and
amplified on a conventional PCR machine. The following
PCR conditions were used; 10 minutes at 95 °C followed
by 18 cycles each consisting of 15 seconds at 95 °C
and 4 minutes at 60 °C. The mixture was diluted 15
times and 2 μl was used for real-time PCR analysis.
The selected SNPs were analyzed using TaqMan
OpenArray® technology (Life Technologies); however,
in case of low call rate, missing samples were reana-
lyzed separately using the Viia7 RealTime PCR system
(Life Technologies).
Statistical analysis
Possible associations between parameters were analyzed
using Pearson’s chi-square test and logistic regression.
Univariate and multivariate odds ratios (ORs), 95 % con-
fidence intervals (CIs), and P values were derived from
logistic regressions. IGF-1R expression and clinical vari-
ables, which have been reported to be associated with
pCR, were tested in univariate analysis (e.g., hormone re-
ceptor (HR) status and clinical T status). The association
between IGF-1R expression and MP classification were
tested using a logistic ordinal regression where MP
classification groups were treated as ordered. In multi-
variate analyses, parameters were adjusted for covariates
with P <0.1. We also reanalyzed the latter model using
Table 2 Patient characteristics
Patients (N = 216) in NEOZOTAC
Median age, years (range) 49.5 (28–70)
Median BMI, kg/m2 (range) 26.2 (18.3–42.0)
Clinical T stage cT1 or cT2 123 (56.9 %)
cT3 or cT4 93 (43.1 %)
Clinical N stage cN0 101 (46.8 %)
cN+ 115 (53.2 %)
Tumor type Ductal 128 (59.3 %)
Lobular 38 (17.6 %)
Other 18 (8.4 %)
Unknown 32 (14.8 %)
HR status ER+ and/or PR+ 180 (83.3 %)
ER– and PR– 36 (16.7 %)
Allocated treatment TAC 109 (50.5 %)
TAC + ZA 107 (49.5 %)
pCR breast and LN Yes 25 (11.6 %)
No 184 (85.2 %)
Unknown 7 (3.2 %)
MP breast 1 33 (15.3 %)
2 56 (25.9 %)
3 41 (19.0 %)
4 42 (19.4 %)
5 35 (16.2 %)
Unknown 9 (4.2 %)
BMI body mass index, ER estrogen receptor, HR hormone receptor, LN lymph
nodes, MP Miller and Payne, pCR pathologic complete response, PR progesterone
receptor, TAC docetaxel, doxorubicin, and cyclophosphamide, ZA zoledronic acid
Table 1 Selected SNPs in IGF-1 pathway
RS number Gene Alleles (major >minor) Position in gene and functionality Clinical influence of polymorphism
rs10735380 IGF1 A > G Transcription factor binding site, intronic Variant G allele associated with increased serum IGF-1
level [20, 35, 41]
rs1520220 IGF1 C > G Intronic Variant G allele associated with increased serum IGF-1
level [35, 42] and BC risk [42].
rs6220 IGF1 A > G 3′-untranslated region, microRNA binding site Variant G allele associated with increased serum IGF-1
level and increased BC risk [42]
rs2946834 IGF1 G > A 3′-untranslated region Variant A allele associated with increased serum IGF-1
level [35, 42] and with worse outcome in BC [21]
rs2270628 IGFBP3 C > T Downstream Variant T allele associated with decreased serum
IGF-BP3 level [20, 35, 36]
rs2854746 IGFBP3 G > C Nonsynonymous in exon 1 Variant C allele associated with increased serum
IGF-BP3 level [20, 35, 36, 43] and with better
outcome in advanced gastric cancer treated
with CT [44]
(Ala32Gly)
rs4320932 IGF2 T > C Transcription factor binding site, intronic Variant C allele associated with worse outcome
in ovarian cancer and worse response to CT [45]
rs2016347 IGF1R G > T 3′-untranslated region, microRNA binding site Variant T allele associated with better outcome in
ER+ BC [22]
SNPs selected on basis of literature research and the clinical influence. rs reference SNP number, BC breast cancer, CT chemotherapy, ER estrogen receptor, IGF
insulin-like growth factor, IGFBP3 insulin-like growth factor binding protein 3, IGF1R insulin-like growth factor 1 receptor, SNP single nucleotide polymorphism
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linear regression to check for linearity of relationship
between IGF-1R expression and MP classification.
Genotype distributions were tested for adherence to
Hardy–Weinberg equilibrium and SNPs significant at the
0.05 level after Bonferroni correction were excluded from
the analysis. Genotypes found to be (borderline) signifi-
cant in the univariate logistic regression models were car-
ried forward to the multivariate model, adjusting for
covariates with P < 0.1. To correct for multiple testing, a
global score test including all SNPs was performed [30].
The score test assumes that the regression coefficients of
the SNPs are normally distributed and tests whether the
variance of this distribution is bigger than zero. In that
case at least one regression coefficient has to be unequal
to zero. To investigate the individual, relative contribution
of SNPs, a classification and regression tree (CART) was
computed (Statistical Package for Social Sciences (SPSS):
classify, tree; (IBM Corp., Armonk, NY, USA)). A receiver
operating characteristic curve and the area under the
curve (AUC) were computed for the predicted probabil-
ities of the CART. The global P value was computed using
the package globaltest in R version 3.1.3 (The R Founda-
tion for Statistical Computing, Institute for Statistics and
Mathematics, Vienna, Austria). All other analyses were
computed using SPSS software™ 20.0 (IBM Corp.). A sig-
nificance level of 0.05 was used for all tests.
Results
Patient characteristics
Patients of both study arms, chemotherapy with or without
zoledronic acid, were included in this study, as no differ-
ences were found between both arms regarding pathological
Fig. 3 Membranous IGF-1R expression before and after treatment and the association with pathological response. *P <0.05. IGF-1R insulin-like
growth factor 1 receptor, MP Miller and Payne
Fig. 2 Consort diagram. FFPE formalin-fixed paraffin-embedded, IHC immunohistochemistry, MP Miller and Payne, pCR pathological complete response,
SNP single nucleotide polymorphism. *Less tumor specimens available for performing IHC due to pCR of no tumor in the analyzed FFPE slide
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response [26]. FFPE tissue was available from 216 (86.4 %)
of 250 patients. Clinical characteristics of the 216 patients
are presented in Table 2, which are comparable with the
characteristics of the entire cohort of the NEOZOTAC
trial [26]. Almost 12 % of the patients had a pCR.
IGF-1R expression
FFPE breast tumor tissue from 216 patients was available
for analyzing at least one condition (biopsy and/or oper-
ation specimen), while both samples were available for 106
cases. Data of available tissue are summarized in the con-
sort diagram (Fig. 2). Representative tissue examples with
different scoring values can be found in Fig. 1. High IGF-
1R expression in the prechemotherapy biopsy was associ-
ated with ER expression (P = 0.001) and the progesterone
receptor (PR) expression (P = 0.035). ER and/or PR-positive
tumors showed positive IGF-1R on the membrane in
78.0 % of the cases, while triple-negative tumors showed
positivity for IGF-1R in only 50.0 % of the cases.
During chemotherapy, a significant subset (47.2 %), of
tumors showed a decrease in IGF-1R expression while in
a small subset of tumors the IGF-1R was upregulated
(15.1 %). IGF-1R expression before treatment was not as-
sociated with pathological response (Fig. 3). However, the
absence of IGF-1R expression (45 %) after treatment in
the postchemotherapy operation specimens was associ-
ated with a better pathological response comparing or-
dinal MP classification response in univariate analysis (OR
2.60, 95 % CI 1.31–5.18, P = 0.006) (Fig. 3). This result
remained significant in multivariate analysis when adjust-
ing for HR status and clinical N stage (OR 2.64, 95 % CI
1.32–5.31, P = 0.006). With linear regression P = 0.008, in-
dicating that the relationship between MP classification
and IGF-1R expression is almost linear. Additionally, pa-
tients with a decrease in expression during treatment
showed a better response to chemotherapy as well (OR
2.64, 95 % CI 1.17–5.98, P = 0.020 in multivariate analysis).
Treatment with zoledronic acid had no influence on the
IGF-1R expression in the operation specimen after treat-
ment (P = 0.620) nor on diminished IGF-1R expression
during treatment (P = 0.830) (data not shown).
IGF-1R pathway SNPs
FFPE tissue samples from 184 (74 %) of 250 patients were
available for analysis of IGF-1 pathway polymorphisms
(preferentially tumor-negative tissue, see Methods). Data of
available tissue are summarized in the consort diagram
(Fig. 2). Of the eight genotyped SNPs, two significantly devi-
ated from the Hardy–Weinberg equilibrium (rs2946834 and
rs1520220). After correction for multiple testing, rs2946834
still significantly deviated from the Hardy–Weinberg equi-
librium and was therefore excluded from the analysis. The
genotype frequencies of rs1520220 did not differ from those
observed in a publicly available database of European
subjects (e.g., from the HapMap project) [28]. All eight
SNPs had a call rate above 85 %, which is shown in Table 3.
Clinical T stage, clinical N stage, and HR status were associ-
ated with pCR, wherefore was adjusted in multivariate ana-
lyses (Table 4). The variant T allele of 3129G >T in IGF1R
(rs2016347) was associated with pCR in multivariate analysis
(4.4 % for GG vs. 16.7 % GT/TT, P= 0.032) and the variant
C allele of rs2854746 in IGFBP3 tended to be associated
Table 3 Distribution of genotypes of the investigated SNPs
SNP Allele N = 184 (%) HWE χ2 P value Call rate (%)
rs10735380 AA 110 (54.3) 2.1 0.144 94
IGF1 AG 68 (37.0)
GG 5 (2.7)
NE 11 (6.0)
rs1520220 CC 115 (62.5) 4.4 0.040a 94
IGF1 CG 46 k
GG 11 (6.0)
NE 12 (6.5)
rs6220 AA 91 (49.5) 3.3 0.068 89
IGF1 AG 56 (30.4)
GG 17 (9.2)
NE 20 (10.9)
rs2946834b GG 82 (44.6) 10.1 0.001a 88
IGF1 GA 53 (28.8)
AA 26 (14.1)
NE 23 (12.5)
rs2270628 CC 105 (57.1) 2.8 0.096 87
IGFBP3 CT 45 (24.5)
TT 10 (5.4)
NE 24 (13.0)
rs2854746 GG 59 (32.1) 1.9 0.170 90
IGFBP3 GC 72 (39.1)
CC 34 (18.5)
NE 19 (10.3)
rs4320932 TT 111 (60.3) 0.04 0.843 96
IGF2 TC 57 (31)
CC 8 (4.3)
NE 8 (4.3)
rs2016347 GG 48 (26.1) 1.8 0.185 96
IGF1R GT 96 (52.2)
TT 32 (17.4)
NE 8 (4.3)
aNot in HWE
bSNP excluded from analyses because the SNP is significantly deviated from
HWE after Bonferroni correction
HWE Hardy–Weinberg equilibrium, IGF insulin-like growth factor, IGFBP3
insulin-like growth factor binding protein 3, IGF1R insulin-like growth factor-1
receptor, NE Not evaluable (despite attempt to genotype), SNP single
nucleotide polymorphism
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with pCR in multivariate analysis (7.3 % for GG vs. 18.1 %
GC/CC, P= 0.058). The global P value used for multiple
testing correction for all eight SNPs together was P= 0.0095
for the dominant model (global score test). The CART de-
rived from these SNPs is shown in Fig. 4. The correspond-
ing AUC was 0.613 (95 % CI 0.518–0.707, P = 0.040).
Moreover, the variant T allele of C > T in IGFBP3
(rs2270628) was associated with a higher occurrence of
grade III/IV side effects in univariate analysis (OR 2.20,
95 % CI 1.04–4.67, P = 0.039) and multivariate analysis
(18.1 % for CC vs. 32.7 % CT/TT, OR 2.30, 95 % CI
1.06–4.98, P = 0.034) (data not shown). The multivariate
Table 4 Associations between tumor and patient characteristics, SNPs, and pCR in breast and lymph nodes
Univariate analysis Multivariate analysis
Parameter N % pCR OR 95 % CI P value OR 95 % CI P value
Clinical T stage cT1/cT2 106 17.9 1 Reference 1 Reference
cT3/T4 73 6.8 0.34 0.12–0.95 0.039 0.49 0.16–1.50 0.209
Clinical N stage cN0 84 21.4 1 Reference 1 Reference
cN+ 95 6.3 0.25 0.09–0.66 0.005 0.19 0.06–0.58 0.003
HR status ER+ and/or PR+ 151 8.6 1 Reference 1 Reference
Triple negative 28 39.3 6.87 2.66–17.7 0.00007 9.35 3.09–28.3 0.00008
Allocated treatment TAC + ZA 87 14.9 1 Reference 0.559
TAC only 92 12.0 0.77 0.33–1.83
Age 0.96 0.89–1.09 0.186
BMI 0.97 0.88–1.08 0.581
rs10735380 AA 97 13.4 1 Reference
IGF1 AG 66 13.6 1.02 0.41–2.55 0.966
GG 5 20.0 1.61 0.17–15.6 0.679
rs1520220 CC 111 15.3 1 Reference
IGF1 CG 45 13.3 0.85 0.31–2.32 0.752
GG 11 0.0 – – –
rs6220 AA 88 11.4 1 Reference
IGF1 AG 56 16.1 1.49 0.57–3.94 0.418
GG 17 17.6 1.67 0.41–6.48 0.475
rs2270628 CC 101 11.9 1 Reference
IGFBP3 CT 45 17.8 1.60 0.61–4.24 0.342
TT 9 0.0 – – –
rs2854746 GG 55 7.3 1 Reference 1 Reference
IGFBP3 GC 72 16.7 2.55 0.78–8.40 0.124 3.06 0.82–11.4 0.097
CC 33 21.2 3.43 0.92–12.8 0.066 4.02 0.92–17.6 0.065
GG 55 7.3 1 Reference 1 Reference
GC/CC 105 18.1 2.82 0.91–8.74 0.073 3.35 0.96–11.7 0.058
rs4320932 TT 106 15.1 1 Reference
IGF2 TC 57 12.3 0.79 0.30–2.04 0.623
CC 8 12.5 0.80 0.09–6.98 0.843
rs2016347 GG 45 4.4 1 Reference 1 Reference
IGF1R GT 94 17.0 4.41 0.97–20.1 0.055 5.58 1.08–28.7 0.040
TT 32 15.6 3.98 0.72–22.0 0.113 6.67 1.03–43.1 0.046
GG 45 4.4 1 Reference 1 Reference
GT/TT 126 16.7 4.30 1.00–19.1 0.056 5.82 1.17–29.1 0.032
BMI body mass index, CI confidence interval, ER estrogen receptor, HR hormone receptor, IGF insulin-like growth factor 1, IGFBP3 insulin-like growth factor binding
protein 3, IGF1R insulin-like growth factor 1 receptor, OR odds ratio, pCR pathological complete response, PR progesterone receptor, SNP single nucleotide
polymorphism, TAC docetaxel, doxorubicin, cyclophosphamide, ZA zoledronic acid
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analysis was adjusted for body mass index, as it was
significantly associated with grade III/IV side effects.
Genotype–phenotype associations
rs2016347 in IGF1R was not associated with IGF-1R
expression before chemotherapy (78.3 % for GG vs.
65.9 % GT/TT, P = 0.115) or after chemotherapy (50.0 %
for GG vs. 67.7 % GT/TT, P = 0.099).
Discussion
This translational study showed that IGF-1R expression
changed in most of the tumors during treatment in
stage II/III HER2-negative BC patients treated with neo-
adjuvant TAC chemotherapy and that absent or dimin-
ished expression after treatment was associated with a
better pathological response according to MP classifica-
tion. Additionally, we found that the variant T allele of
3129G > T in IGF1R (rs2016347) was significantly associ-
ated with a better pathological response according to
MP classification after neoadjuvant chemotherapy.
Changes of IGF-1R expression of the tumor during
chemotherapy have been described previously [18, 31].
Our study confirms these results in a larger and more
homogeneous patient cohort. Moreover, in the current
trial a greater part of the tumors showed a decline in
IGF-1R expression (47.2 %) compared with the prior de-
scribed 14.0 %. This might be explained by the difference
in chemotherapy regimens used as well as the absence
of HER2 expression in our cohort, as HER2-positive tu-
mors show less IGF-1R expression [10, 11]. The decline
of IGF-1R expression in the tumor during TAC treat-
ment observed in our study might reflect chemotherapy
efficacy, as patients with a decline in IGF-1R expression
showed a significantly better pathological response than
Fig. 4 CART analyses of pCR in BC patients treated with TAC chemotherapy. The tree is divided by the SNPs to predict pCR, which has a
significant prediction score (AUC 0.613 95 % CI 0.518–0.707, P = 0.040). IGFBP3 insulin-like growth factor binding protein 3, IGF1R insulin-like
growth factor 1 receptor, pCR pathological complete response
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tumors with no change or an increase in expression. In
keeping with this inference, downregulation of IGF-1R
during chemotherapy treatment is associated with pro-
longed survival [18]. Bhargava et al. [10] showed that
low IGF-1R expression before treatment was associated
with a better response to neoadjuvant chemotherapy in
ER-positive tumors, but not in triple-negative tumors.
We could not reproduce this association, but this could
be explained by the difference in cohort (e.g., differences
in HER2 status and chemotherapy regimen).
In our exploratory analysis of IGF-1 pathway polymor-
phisms, the variant T allele of 3129G > T in IGF1R
(rs2016347) was associated with a better pathological re-
sponse according to MP classification after neoadjuvant
chemotherapy. This is in accordance with studies that
associated 3129G > T in IGF1R (rs2016347) with cancer
prognosis and treatment outcome [22, 32, 33]. Winder
et al. [22] found that the T allele was associated with a
better overall survival in colorectal cancer patients
treated with cetuximab [33] and a better overall survival
in ER-positive BC patients treated with tamoxifen.
rs2016347 is localized in the 3′-untranslated region of
the IGF1R gene, functioning as a microRNA binding site
[28]. Because microRNA binding sites are important for
mRNA translation and degradation, the variant T allele
of rs2016347 might disturb binding to this microRNA
site [34]. Although the precise functional effect of IGF1R
rs2016347 is unknown, it would be a plausible explan-
ation that the T allele of rs2016347 may reduce IGF-1R
expression. However, in our study rs2016347 in IGF1R
was not associated with IGF-1R expression.
The variant T allele of C > T in IGFBP3 (rs2270628)
was associated with the occurrence of grade III/IV side
effects. Although the mechanism is unclear, several stud-
ies have shown that the variant T allele of rs2270628 is
associated with decreased serum IGF-BP3 levels [35, 36].
IGF-1 activity depends on binding with IGF-BP3 [12, 13],
so it may be that higher activity of IGF-1 due to lower
levels of IGF-BP3 causes a higher incidence of toxicity of
chemotherapy in our study [6].
Our study has some limitations. Using our approach,
we could not investigate the best responders (MP5) after
chemotherapy because inherently no tumor tissue was
left to measure IGF-1R in the operation specimen.
Moreover, the response of the lymph nodes is not evalu-
ated in the MP grading system because it focuses only
on the primary tumor. Although, the survival of patients
with a partial response is affected by residual lymph
node status [37]. Additionally, the number of evaluable
triple-negative tumors was too small to evaluate for dif-
ferences in response associated with IGF-1R between
HR-positive tumors and triple-negative tumors. Our
sample size for the explorative genotype–phenotype op-
tional side study was small and this was probably the
reason why we could not reproduce the associations be-
tween the serum IGF-1 and IGF-BP3 levels and SNPs.
However, the results of our study provide further evi-
dence for the importance of patient selection for
(co)treatment with an IGF-1 inhibitor. Until now no
convincing benefit of IGF-I pathway inhibitors was
found in clinical studies in BC [38–40]. These studies
lacked patient selection based on IGF-1 pathway activity.
It may be hypothesized that patients with a diminished
IGF-1R after chemotherapy will not benefit from an
IGF-1R inhibitor, while a patient with upregulated IGF-
1R might benefit.
Conclusions
IGF-1R expression in the tumor changed during chemo-
therapy and absent or diminished expression of IGF-1R
after treatment was associated with a better pathological
response. rs2016347 in IGF1R was associated with pCR
after TAC chemotherapy. These observations may help
to predict the efficacy of TAC chemotherapy and to
select patients who might benefit from (co)treatment
with an IGF-1 pathway inhibitor.
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